Law Firm Probes Pacira BioSciences Over Shareholder Rights
Monteverde & Associates has opened an investigation into Pacira BioSciences, a move that could signal potential M&A-related legal action for PCRX shareholders.
A New York-based class action law firm has announced it is investigating Pacira BioSciences, Inc., the Nasdaq-listed pharmaceutical company trading under the ticker PCRX, according to a statement released in October 2026.
Monteverde & Associates PC, led by attorney Juan Monteverde, disclosed the probe, which the firm indicated relates to potential shareholder rights concerns. The firm describes itself as a mergers-and-acquisitions-focused class action practice and says it has recovered millions of dollars on behalf of investors in prior cases.
Read more Law Firm Probes Option Care Health Over Shareholder Rights →
The firm was recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, a benchmark used in the legal and institutional investment community to evaluate plaintiff-side securities litigation practices. That recognition lends some institutional credibility to the firm's investigative announcements, though an investigation does not itself constitute a filed lawsuit or confirmed wrongdoing.
Shareholder investigations of this nature typically precede potential class action lawsuits and often arise in the context of mergers, acquisitions, or other corporate transactions where investors believe they may not have received full value or adequate disclosure. Pacira BioSciences shareholders are being encouraged by the firm to contact it directly for more information about their legal rights and options.
The source article did not specify the precise nature of the transaction or conduct under scrutiny. Continue reading at All Financial Services & Investing.
